BriaCell presents remarkable responder data in combo study with KEYTRUDA

Dr. William Williams, president and CEO of BriaCell Therapeutics (TSX-V:BCT; OTCQB:BCTXF) presented clinical updates of its Phase 1/2a clinical trial of Bria-IMT, its lead drug candidate, in a combination study with KEYTRUDA in patients with advanced breast cancer at the 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia.

The top responder in the combination study experienced a highly remarkable reduction in breast cancer tumors.  She is an advanced breast cancer patient who had failed 12 prior regimens with 16 chemotherapy and hormonal agents.

She showed one of the best immune responses and displayed a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain during the combination study.  

Prior to enrollment in the combination study, she had progressive cancer in spite of aggressive treatment with some of the newest therapies.  She remains on the combination study treatment.

“We are thrilled to see these impressive clinical findings in the combination study that confirm our hypothesis of clinical benefit (tumor shrinkage without serious side effects) in advanced breast cancer patients who had failed multiple prior treatments,” Dr. Williams said in a statement.

“In our view, these results support the clinical efficacy (i.e. additive or synergistic effects) that we previously observed in advanced breast cancer patients,” he added.

The data presented also noted that the Bria-IMT regimen administered with KEYTRUDA was safe and well tolerated. The women who showed the best clinical responses to the combination also showed the best immune responses, including a cellular immune response and a humoral immune response. 

Additional patient data sets will be presented at the San Antonio Breast Cancer Symposium on Dec. 10-14, 2019.


Sign up to our weekly BioTuesdays newsletter.